Loading
Bicara Therapeutics Inc. Stock: price and insider trades · United States
US·Mcap US$1.1B
No insider purchase over the last 90 days. The latest was filed 02 Mar 2026.
Bicara Therapeutics Inc.: what insiders have been doing
Bicara Therapeutics Inc. is a listed company. Its directors and officers file their transactions with SEC (Form 4). Between 18 October 2025 and 18 October 2026, 10 insiders published 70 filings.
On the market, 1 insider bought (1 purchase totalling €4.1M) while 4 insiders sold (22 sales totalling €4.1M). Taken together, the sales exceed the purchases by €22k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. At €4.1M, the purchase published on 2 March 2026 by RA Capital Management, L.P. is the largest of the period. The buyers include 1 senior executive.
The latest purchase dates back some time: it was published 230 days ago, on 2 March 2026. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Across the 5,808 companies tracked on its exchange, the median is 19 filings; at 70 filings, this issuer sits above that mark. Over the whole record (from 2024), the tally stands at 1 purchase and 22 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -137.9 m USD.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
87
Thresholds
n/a
Buy Volume
€4M
1 ops. · all time
Sell Volume
€4M
22 ops. · all time
Who traded when
BuySaleRyan Cohlhepp11 sales
Hyep Ivan6 sales
Claire Mazumdar4 sales
RA Capital Management, L.P.1 buy
Raben David1 sale
Since the insiders bought
- -4.2%Entry US$17.92 · Close 14 Oct 2026 US$17.16
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Bicara Therapeutics Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$35.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$17.33
Analyst consensus
12 analystsStrong buy
US$20.00Target US$35.50(+105%)US$45.00
Income statement
EBITDA-US$155.5M
Net income-US$138M0.0% margin
Valuation
PER (forward)-4.9x
P/Book2.4x
Beta-0.69
Balance sheet & cash
Market capUS$1.1B
Total debtUS$1.7M
Free Cash Flow-US$107.1M
Debt / Equity0%
Profitability & ownership
ROE-41.0%
ROA-26.1%
% insiders10.1%
% institutions102.3%
Last declaration on 10 September 2026
Declarations87 total
17,500 shares@ US$3.78980.0050% mcap1.5% of flowCommon StockSEC:0001470831-26-000883:0
14,058 shares@ US$22.76660.024% mcap7.0% of flowCommon StockSEC:0001470831-26-000883:1
3,442 shares@ US$23.43490.0060% mcap1.8% of flowCommon StockSEC:0001470831-26-000883:2
17,500 shares@ US$22.640.030% mcap8.7% of flowCommonSEC144:0001969223-26-001008
18,750 shares@ US$3.78980.0053% mcap1.6% of flowCommon StockSEC:0001470831-26-000812:0
18,750 shares@ US$27.97510.039% mcap11.6% of flowCommon StockSEC:0001470831-26-000812:1
10,000 shares@ US$3.78980.0029% mcap1.6% of flowCommon StockSEC:0001470831-26-000813:0
10,000 shares@ US$27.9750.021% mcap11.9% of flowCommon StockSEC:0001470831-26-000813:1
10,000 shares@ US$27.830.021% mcap11.9% of flowCommonSEC144:0001969223-26-000869
18,750 shares@ US$27.830.039% mcap11.5% of flowCommonSEC144:0001969223-26-000872
9,972 shares@ US$28.41630.022% mcap12.2% of flowCommon StockSEC:0001470831-26-000714:1
28 shares@ US$29.680.0001% mcap0.0% of flowCommon StockSEC:0001470831-26-000714:2
10,000 shares@ US$3.78980.0029% mcap1.6% of flowCommon StockSEC:0001470831-26-000714:0
10,000 shares@ US$29.680.023% mcap12.8% of flowCommonSEC144:0001969223-26-000775
18,750 shares@ US$3.78980.0054% mcap1.6% of flowCommon StockSEC:0001470831-26-000701:0
4,306 shares@ US$29.79610.0098% mcap2.9% of flowCommon StockSEC:0001470831-26-000701:2
1,075 shares@ US$30.35490.0025% mcap0.7% of flowCommon StockSEC:0001470831-26-000701:3
536 shares@ US$29.000.0012% mcap0.3% of flowCommon StockSEC:0001470831-26-000701:4
25 of 87 declarations
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. It employs immunotherapy-based approaches to target tumors.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
